Incidence of de Novo Hepatocellular Carcinoma After Antiviral Agents for HCV.
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03775798 |
|
Recruitment Status : Unknown
Verified December 2018 by Maria Julia Cremona, Austral University, Argentina.
Recruitment status was: Recruiting
First Posted : December 14, 2018
Last Update Posted : December 19, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The main risk factor for development of hepatocellular carcinoma (HCC) is cirrhosis of any etiology, with an annual incidence risk between 1-6%; currently the leading cause of death in patients with cirrhosis and the 2nd cause of death by cancer worldwide. Chronic hepatitis C (HCV) is the first single cause associated to cirrhosis and HCC in the Western world.
With the advent of new direct antiviral agents (DAA) of chronic HCV infection, virological cure generally exceeds 90% of the cases. Previous studies have shown that the incidence of HCC is lower in patients with virologic cure after treatment with pegINF schemes. However, recently published data, open up more controversy regarding the incidence of HCC after virologic cure with DAA. An increasing incidence of HCC after virologic cure in patients treated with DAA has been observed, opening a paradox yet unexplained.
This project proposes to answer the following clinical research question: in patients with HCV cirrhosis treated with DAA, is there a change in the incidence of hepatocellular carcinoma? To answer this question a prospective longitudinal cohort study of patients with Child Pugh A-B cirrhosis will be held at 3 years minimum follow-up.
A minimum of 210 patients will be included with clinical or histological or non-invasive diagnosis of cirrhosis Child Pugh A or B, with HCV treated with DAA and without hepatocellular carcinoma at the time of enrollment. From this cohort, patients who develop HCC during follow-up will be identified. Routine screening will be done through ultrasound every 6 months in all subjects enrolled and the diagnosis of HCC will be according to recommendations of European and American guidelines.
| Condition or disease | Intervention/treatment |
|---|---|
| Hepatitis C Cirrhosis Antiviral Drug Adverse Reaction | Drug: Direct antiviral agents for hepatitis C |
Name of the study:
INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS WITH HEPATITIS C INFECTION, TRETAED WITH DIRECT ANTIVIRAL AGENTS IN LATIN AMERICA: A MULTICENTER PROSPECTIVE COHORT STUDY
With the advent of new direct antiviral agents (DAA) of chronic HCV infection, virological cure generally exceeds 90% of the cases. Previous studies have shown that the incidence of HCC is lower in patients with virologic cure after treatment with pegINF schemes. However, recently published data, open up more controversy regarding the incidence of HCC after virologic cure with DAA. An increasing incidence of HCC after virologic cure in patients treated with DAA has been observed, opening a paradox yet unexplained.
This project proposes to answer the following clinical research question: in patients with HCV cirrhosis treated with DAA, is there a change in the incidence of hepatocellular carcinoma? To answer this question a prospective longitudinal cohort study of patients with Child Pugh A-B cirrhosis will be held at 3 years minimum follow-up.
A minimum of 210 patients will be included with clinical or histological or non-invasive diagnosis of cirrhosis Child Pugh A or B, with HCV treated with DAA and without hepatocellular carcinoma at the time of enrollement. From this cohort, patients who develop HCC during follow-up will be identified. Routine screening will be done through ultrasound every 6 months in all subjects enrolled and the diagnosis of HCC will be according to recommendations of European and American guidelines.
However, preliminary results presented at the last European Congress of Hepatology in Barcelona, Spain, and early published in Journal of Heaptology, open up more controversy regarding the incidence of HCC after virologic cure post DAA. An unexpected higher incidence and recurrence of HCC after treatment with these new drugs has been observed, opening a paradox yet unexplained. Of particular interest then, is to clarify and find if there is a change in the incidence of HCC in HCV cirrhosis after treatment with DAA in our region. It is relevant on the other hand; that this study would be the first longitudinal cohort study evaluating the development of HCC in patients with cirrhosis in Latin America. It is then expected that the results would be extremely important to the medical science from this region.
Clinical Research Question In patients with HCV cirrhosis treated DAA, is there a change in the incidence of hepatocellular carcinoma? Primary Objective To evaluate the incidence of HCC after treatment with DAA in patients with Child Pugh A or B cirrhosis and chronic HCV infection.
Secondary Objectives
Secondary objectives will be related to:
- Incidence of HCC between cured and uncured of HCV with DAA.
- Impact of routine screening on survival in patients with HCC.
- Risk factors for development of hepatocellular carcinoma in patients with HCV treated with DAA.
- Adverse events and incidence of cirrhosis decompensation after DAA.
| Study Type : | Observational [Patient Registry] |
| Estimated Enrollment : | 2200 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Target Follow-Up Duration: | 36 Months |
| Official Title: | Incidence of de Novo Hepatocellular Carcinoma After Direct-acting Antiviral Agents for HCV: a Multicenter Prospective Cohort Study From Latin America. |
| Actual Study Start Date : | May 1, 2016 |
| Estimated Primary Completion Date : | December 1, 2020 |
| Estimated Study Completion Date : | January 1, 2021 |
- Drug: Direct antiviral agents for hepatitis C
Direct-acting antivirals for hepatitis C
- Incidence of hepatocellular carcinoma after direct-acting antivirals for HCV [ Time Frame: Three year period ]Cumulative incidence, Hazard ratios (95% CI)
- Effectiveness of direct-acting antivirals for HCV [ Time Frame: Three year period ]Achievement of RVS
- Adverse events after direct-acting antivirals for HCV [ Time Frame: Three year period ]Safety
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Signed Informed Consent (CI) obtained prior to any study specific procedure. Patients should be able to understand written informed and be ready to sign it (ANNEX I).
- Men and women 18 years or older.
- Clinical, histological or non-invasive diagnosis of cirrhosis, according to the American Association for the Study of Liver Diseases, AASLD criteria) [15].
- Child Pugh A or B (ANNEX II). Child Pugh classification should be calculated based on clinical findings and laboratory results during the selection period.
- Chronic Hepatitis C, defined as positive viremia with real time PCR method.
- Current or prior treatment with DAA, including any interferon-free scheme, either in a clinical protocol or treated in the daily practice.
- Co-infection with HIV infection is allowed or Hepatitis B.
Exclusion Criteria:
-
• Prior diagnosis of Hepatocellular to treatment with DAA.
- Previous liver transplantation.
- Drug addiction, medical, psychological or social problems that may interfere with the patient's participation in the study or evaluation of the results.
- Pregnancy and/or breastfeeding.
- Close relationship with the research center; eg close family member of the researcher, dependent (eg employee or student research center that could access study records and data CRF).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03775798
| Contact: Maria Julia Cremona | MCREMONA@austral.edu.ar | ||
| Contact: Marcelo Silva, MD | msilva@cas.austral.edu.ar |
| Argentina | |
| Universidad Austral | Recruiting |
| Pilar, Buenos Aires, Argentina, 1629 | |
| Contact: Marcelo Silva, MD msilva@cas.austral.edu.ar | |
| Contact: Federico Piñero, MD, MSCE fpinerof@cas.austral.edu.ar | |
| Principal Investigator: Marcelo Silva, MD | |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Maria Julia Cremona, UIC staff, Austral University, Argentina |
| ClinicalTrials.gov Identifier: | NCT03775798 |
| Other Study ID Numbers: |
17-062 |
| First Posted: | December 14, 2018 Key Record Dates |
| Last Update Posted: | December 19, 2018 |
| Last Verified: | December 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
|
direct acting antivirals hepatitis c hepatocellular carcinoma |
|
Hepatitis C Carcinoma Carcinoma, Hepatocellular Hepatitis Drug-Related Side Effects and Adverse Reactions Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases |
Infections RNA Virus Infections Blood-Borne Infections Communicable Diseases Flaviviridae Infections Adenocarcinoma Liver Neoplasms Digestive System Neoplasms Neoplasms by Site Chemically-Induced Disorders Antiviral Agents Anti-Infective Agents |